Nonstatin Prescriptions Increasing, Still Behind Statins in ASCVD, With Michael Blaha, MD, MPH

9 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Since 2019, nonstatin lipid-lowering therapy (LLT) prescription has expanded substantially among patients at risk for atherosclerotic cardiovascular disease (ASCVD), according to a recent study; however, it still has not closed the gap with statins.
A plethora of recent research has reinforced the efficacy of nonstatin LLTs in the reduction of ASCVD risk, and several therapies have received approval to lower LDL-C and other atherogenic lipoproteins. Among these are ezetimibe, bile acid sequestrants, PCSK9 inhibitors, bempedoic acid, fibrates, icosapent ethyl, and niacin. Additionally, recently published guidelines have recommended the addition of nonstatin LLTs when statin therapies are insufficient. However, implementation has lagged behind that of statins over the years.
In an interview with HCPLive, Michael Blaha, MD, MPH, professor of cardiology and epidemiology, director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, and co-author of the present study, discusses the importance of wider adoption of nonstatin LLTs and the preventive abilities they're already proven to have.

“In some cases, clinicians think of statins as a simple yes or no,” Blaha said. “Of course, the new guidelines are really going to push people to think more about LDL goals. Statins will remain the cornerstone of therapy, but maybe only step 1. Maybe you need step 2 or step 3 after that, with the addition of nonstatin therapy and, of course, more appreciation of statin intolerance and how best to handle that."

Read the full article here: https://www.hcplive.com/view/nonstatin-prescriptions-increasing-still-behind-statins-in-ascvd-with-michael-blaha-md-mph

Key Timestamps
00:00:01 Intro
00:00:08 Publication overview
00:00:55 Interpreting rising nonstatin prescriptions
00:01:54 Statins as the endpoint vs the foundation
00:02:54 Keeping up with the guidelines
00:04:29 In-clinic interventions
00:05:52 Optimal lipid management in the clinic

#cardiology #statin #lipids
Categoria
Cardiology
Commenta per primo questo video.

Prossimo